Lifting the Brain Fog: HCV and Depression in the DAA Era
If you only have time for one article, rummage around the cover story. Experts weigh in on the topic of depression associated with chronic hepatitis C, and what role newer HCV regimens play in alleviating the all too familiar symptom.
An excerpt; "Lifting the Brain Fog: HCV and Depression in the DAA Era"
In the current generation of direct-acting antiviral agents, a new wave of data is showing that, apart from remarkably high 12-week sustained virological response rates, novel treatments are demonstrating effectiveness in reducing depression and depressive symptoms in HCV. However, whether they will prove to be a cure for depression remains to be seen. The clinical community is attempting to untangle the physiological and treatment-related effects of HCV on the neurocognitive system in the DAA era.
HCV NEXT
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, fatty liver disease and more.
Table of Contents
5 Questions
A Conversation with Paul J. Pockros, MD
The Big Picture
Staying Current on HCV: A Summary of Recent Updates to the Guidelines
Sujit V. Janardhan, MD, PhD; Nancy S. Reau, MD
The Take Home
Trend Watch
NIH Launches Study to Evaluate Community-Based HCV Therapy
ACH-3102/Sofosbuvir Yields High SVR Rates in Patients with HCV
HCV, Compound Medications Increased Overall US Spending in 2014
FDA Warns of Cardiac Reactions with Sofosbuvir Drug Combinations
Bristol-Myers Squibb Resubmits New Drug Application for Daclatasvir
NIH Awards $1.2 Million Grant for Rapid HCV Test
No comments:
Post a Comment